ロード中...
Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer
Immune-checkpoint inhibitors (ICI), specifically inhibitors of programmed death ligand-1 (PD-L1) and receptor (PD-1) are the new standard of care for the treatment of patients with advanced non-small cell lung cancer (NSCLC) in front line setting as monotherapy or along with chemotherapy. Many of th...
保存先:
| 出版年: | BMJ Case Rep |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449356/ https://ncbi.nlm.nih.gov/pubmed/32843385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-236101 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|